# Gout - Pathophysiology and Management

## Introduction

Gout is the most common inflammatory arthritis worldwide, affecting approximately 4 percent of adults in the United States, with prevalence continuing to rise due to the increasing burden of obesity, metabolic syndrome, an aging population, and widespread diuretic use. The disease is caused by the deposition of monosodium urate crystals in joints and soft tissues, resulting from sustained hyperuricemia that exceeds the physiologic solubility threshold of uric acid. Gout is unique among rheumatic diseases in that it is essentially curable with appropriate urate-lowering therapy, yet it remains remarkably undertreated, with fewer than half of diagnosed patients achieving target serum urate levels. The 2020 ACR guidelines and 2023 EULAR recommendations provide comprehensive evidence-based frameworks for the management of this disease, emphasizing a treat-to-target approach that parallels strategies used in other chronic conditions.

## Pathophysiology

### Uric Acid Metabolism

Uric acid is the end product of purine metabolism in humans, a consequence of the evolutionary loss of the uricase enzyme approximately 15 million years ago, which leaves humans unable to further degrade urate to the more soluble allantoin. Purine sources are divided between endogenous pathways, including cell turnover and de novo synthesis, which account for approximately 70 percent of the urate pool, and dietary or exogenous purines, which contribute the remaining 30 percent. The enzyme xanthine oxidase catalyzes the final two steps in purine degradation, converting hypoxanthine to xanthine and then xanthine to uric acid, making it the pharmacologic target of allopurinol and febuxostat. The solubility threshold of serum urate is 6.8 milligrams per deciliter at 37 degrees Celsius, above which monosodium urate crystals can form. The normal urate pool is approximately 1200 milligrams, with daily production of 700 to 800 milligrams. Approximately two-thirds of urate is excreted renally, while the remaining one-third undergoes intestinal excretion mediated by the ABCG2 transporter.

### Renal Urate Handling

Approximately 90 percent of gout cases are attributable to underexcretion of urate rather than overproduction, underscoring the central importance of renal urate handling in disease pathogenesis. In the proximal tubule, urate is reabsorbed by the transporters URAT1, encoded by the SLC22A12 gene, and GLUT9, encoded by SLC2A9, while secretion occurs via OAT1, OAT3, and ABCG2. URAT1 is the major reabsorptive transporter and represents the pharmacologic target of uricosuric agents such as lesinurad and probenecid. ABCG2 functions as both an intestinal and renal secretory transporter, and loss-of-function variants in this gene are a significant cause of gout, particularly in East Asian populations where the Q141K variant is common. The fractional excretion of uric acid provides a clinical tool for distinguishing the mechanism of hyperuricemia: a value below 5 percent suggests underexcretion, while a value above 10 percent suggests overproduction.

### Crystal Formation and Inflammation

Monosodium urate crystal nucleation requires sustained hyperuricemia, typically over years to decades, before clinically significant crystal deposition occurs. Crystal formation is favored by lower temperatures, which explains the predilection for peripheral joints such as the first metatarsophalangeal joint, as well as by lower pH and states of dehydration. Once formed, MSU crystals activate the NLRP3 inflammasome within macrophages, triggering caspase-1 activation and the subsequent release of interleukin-1 beta, which drives the intense neutrophilic inflammation characteristic of an acute gout flare. Neutrophil extracellular traps formation around MSU crystals further amplifies the inflammatory cascade. Paradoxically, the resolution of gout flares involves aggregated NETs, which may actually promote resolution, along with coating of crystals by proteins including apolipoproteins that dampen their inflammatory potential. In chronic tophaceous gout, a granulomatous response develops around crystal deposits, with multinucleated giant cells, macrophages, and fibroblasts forming organized structures around the urate core.

### Genetic Factors

More than 30 genetic loci have been associated with serum urate levels through genome-wide association studies. The SLC2A9 gene encoding GLUT9 is the strongest genetic determinant of serum urate levels. ABCG2 is the second strongest, with the Q141K variant being particularly common among patients with gout. SLC22A12 encoding URAT1 influences renal reabsorption of urate. The overall heritability of serum urate levels is estimated at 40 to 70 percent, indicating a substantial genetic contribution to hyperuricemia susceptibility, though environmental and comorbid factors remain important modifiable determinants.

<image>A detailed diagram of uric acid metabolism and renal handling. Top section: Purine metabolism pathway showing adenine and guanine breakdown through hypoxanthine and xanthine to uric acid via xanthine oxidase (XO), with allopurinol and febuxostat marked as XO inhibitors. Middle section: The renal proximal tubule showing urate transporters on apical and basolateral membranes - URAT1 and GLUT9 for reabsorption (with probenecid and lesinurad blocking URAT1), OAT1/OAT3 for basolateral uptake, and ABCG2/MRP4 for secretion. Bottom section: The NLRP3 inflammasome activation by MSU crystals showing crystal phagocytosis by macrophage, lysosomal rupture, NLRP3 assembly, caspase-1 activation, and IL-1beta release (with anakinra, canakinumab, and colchicine marked at their points of action). Use clear labels and directional arrows.</image>

## Clinical Manifestations

### Stages of Gout

Gout progresses through four recognizable clinical stages. Asymptomatic hyperuricemia represents an elevated serum urate level without any clinical symptoms, and it is important to recognize that most hyperuricemic individuals never develop gout. Treatment of asymptomatic hyperuricemia is not recommended by current guidelines. The acute gout flare is characterized by dramatic onset of joint inflammation over hours, with peak intensity typically reached within 12 to 24 hours and spontaneous resolution occurring within 7 to 14 days even without treatment. Intercritical gout refers to the asymptomatic periods between flares during which MSU crystals persist in joints and can be identified by ultrasound or dual-energy CT, demonstrating that the disease remains active even in the absence of symptoms. Chronic tophaceous gout develops after years of inadequately treated disease and is characterized by visible tophi, chronic arthritis, and progressive joint destruction.

### Acute Gout Flare

The first metatarsophalangeal joint, referred to as podagra, is involved in approximately 50 percent of first attacks and is affected at some point in 90 percent of gout patients. Other commonly affected sites include the ankle, midfoot, knee, wrist, finger joints, and olecranon bursa. Physical examination reveals exquisite tenderness, erythema that may be severe enough to mimic cellulitis, swelling, and warmth. Systemic features including fever and leukocytosis may accompany the flare, creating a clinical picture that can closely mimic septic arthritis, necessitating synovial fluid analysis for definitive distinction. Common triggers for acute flares include dietary excess involving red meat, shellfish, and beer, dehydration, surgery, trauma, acute illness, medication changes including both the initiation and discontinuation of urate-lowering therapy, and diuretic use.

### Tophaceous Gout

Tophi are nodular deposits of monosodium urate crystals surrounded by granulomatous inflammation. They develop in characteristic locations including the ear helix, olecranon bursae, Achilles tendon, finger pads, and extensor surfaces of the forearms. Tophi can erode bone, destroy cartilage, and cause significant joint deformity when left untreated. They may drain chalky white material consisting of crystalline urate, and they can mimic rheumatoid nodules, making aspiration or biopsy appropriate when diagnostic uncertainty exists.

### Gout in Specific Populations

Gout exhibits distinct features in certain populations. In women, gout is rare before menopause because estrogen exerts a uricosuric effect; postmenopausal gout is more often polyarticular, involves the upper extremities, and is frequently associated with diuretic use. Transplant recipients are at increased risk due to cyclosporine-induced hyperuricemia, which occurs through inhibition of URAT1, and tacrolimus is less hyperuricemic as an alternative calcineurin inhibitor. Patients with chronic kidney disease have an increased prevalence of gout and require medication dose adjustments. Gout is also an integral component of metabolic syndrome and functions as an independent cardiovascular risk factor, underscoring the importance of comprehensive cardiometabolic assessment in gout patients.

## Diagnosis

### Synovial Fluid Analysis (Gold Standard)

Arthrocentesis remains essential for the definitive diagnosis of gout and simultaneously excludes septic arthritis, which is of paramount importance given the clinical overlap between these conditions. Under compensated polarized light microscopy, monosodium urate crystals appear as needle-shaped structures with strong negative birefringence, appearing yellow when aligned parallel to the slow axis of the red compensator and blue when perpendicular. The synovial fluid cell count typically ranges from 10,000 to 70,000 white blood cells per microliter with neutrophilic predominance. Gram stain and culture should always be sent because gout and septic arthritis can coexist in approximately 1 to 2 percent of cases. The identification of intracellular crystals within neutrophils confirms active crystal-induced inflammation and provides the most specific diagnostic finding.

### Imaging

Dual-energy CT identifies urate crystal deposits in joints and soft tissues with a sensitivity of 78 to 100 percent and specificity of 89 to 100 percent for established gout, though sensitivity is reduced in early disease or during a first gout flare. Ultrasound demonstrates the double contour sign, a hyperechoic line over the articular cartilage surface representing urate deposition, as well as tophi and a snowstorm appearance within joint effusions. Conventional radiographs reveal late findings including punched-out erosions with overhanging margins known as the Martel sign, characteristically preserved joint space until late in the disease, and soft tissue tophi with calcification. CT and MRI are useful for tophi evaluation, erosion assessment, and preoperative planning.

### 2015 ACR/EULAR Gout Classification Criteria

The 2015 ACR/EULAR classification criteria require an entry criterion of at least one episode of joint or bursal swelling, pain, or tenderness. A sufficient criterion for classification as gout exists when MSU crystals are identified in synovial fluid or within a tophus. When crystal analysis has not been performed, a scoring system incorporating clinical, laboratory, and imaging features can be applied, with a score of 8 or greater classifying the patient as having gout.

## Management

### Acute Gout Flare Treatment

Colchicine is most effective when administered within 12 to 24 hours of flare onset. The low-dose regimen validated by the AGREE trial consists of 1.2 milligrams followed by 0.6 milligrams one hour later, then 0.6 milligrams daily or twice daily thereafter, providing equivalent efficacy to high-dose regimens with significantly fewer gastrointestinal side effects. Dose adjustment is required in chronic kidney disease, and concomitant use with strong CYP3A4 or P-glycoprotein inhibitors such as clarithromycin and cyclosporine must be avoided due to the risk of life-threatening toxicity.

NSAIDs should be used at full anti-inflammatory doses for 5 to 7 days, with effective regimens including indomethacin 50 milligrams three times daily, naproxen 500 milligrams twice daily, or celecoxib 800 milligrams followed by 400 milligrams. These agents should be avoided in patients with chronic kidney disease, heart failure, or active peptic ulcer disease.

Glucocorticoids represent an equally effective alternative, with the COMPARE trial demonstrating that prednisolone 35 milligrams daily was non-inferior to naproxen 500 milligrams twice daily for acute gout. Systemic therapy with prednisone 30 to 40 milligrams daily for 5 days is effective for polyarticular flares, while intra-articular injection with triamcinolone 40 milligrams for large joints is preferred for monoarticular involvement. Intramuscular triamcinolone 60 milligrams is a useful option when the oral route is difficult.

IL-1 inhibitors are reserved for refractory flares when colchicine, NSAIDs, and glucocorticoids are all contraindicated or ineffective. Anakinra 100 milligrams subcutaneously daily for 3 to 5 days is used off-label based on supportive observational data. Canakinumab 150 milligrams as a single subcutaneous dose is approved in the European Union but not in the United States for gout. Combination therapy with colchicine plus an NSAID or colchicine plus a glucocorticoid may be necessary for severe polyarticular flares.

### Urate-Lowering Therapy (ULT)

#### Indications for ULT (2020 ACR)

The 2020 ACR guidelines conditionally recommend urate-lowering therapy for patients with 2 or more flares per year, the presence of tophi, or radiographic damage attributable to gout. ULT is conditionally recommended against for a first gout flare or for asymptomatic hyperuricemia. The target serum urate level is below 6 milligrams per deciliter following a treat-to-target strategy, with some guidelines suggesting a target below 5 milligrams per deciliter for patients with tophaceous gout to accelerate tophus dissolution.

#### Xanthine Oxidase Inhibitors (First-line)

Allopurinol is the first-line urate-lowering therapy per 2020 ACR guidelines, conditionally recommended over febuxostat. The starting dose is 100 milligrams daily, reduced to no more than 100 milligrams in patients with chronic kidney disease stage 3 or greater, with titration by 100 milligrams increments every 2 to 4 weeks until the serum urate target is achieved. The maximum dose is 800 milligrams daily, and importantly, the 2020 ACR guidelines do not impose a dose ceiling based on renal function but recommend slower titration in patients with kidney disease. HLA-B*5801 testing is mandatory before initiating allopurinol in patients of Southeast Asian, African American, and Korean descent, as this allele is strongly associated with severe allopurinol hypersensitivity syndrome, including DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis, which carries a mortality rate of 20 to 30 percent. Allopurinol hypersensitivity typically occurs within the first 2 to 3 months of therapy and is more common in patients with chronic kidney disease and those taking diuretics.

Febuxostat is a non-purine selective xanthine oxidase inhibitor dosed at 40 to 80 milligrams daily that does not require renal dose adjustment. The CARES trial reported that febuxostat was associated with higher cardiovascular and all-cause mortality compared to allopurinol, leading to an FDA black box warning. However, the larger FAST trial, conducted with more robust methodology, found no difference in cardiovascular events between the two agents. The FREED trial from Japan actually demonstrated that febuxostat reduced cardiovascular events compared to placebo in hyperuricemic patients with cardiovascular risk factors. The current ACR recommendation favors allopurinol over febuxostat, with febuxostat reserved for patients who are allopurinol-intolerant or have failed to reach target on allopurinol.

#### Uricosurics

Probenecid is dosed at 500 milligrams twice daily and can be increased to 2 grams daily. It blocks URAT1-mediated reabsorption but requires adequate renal function with an estimated glomerular filtration rate above 50 milliliters per minute and should be avoided in patients with a history of uric acid nephrolithiasis. Adequate hydration and urine alkalinization are important adjunctive measures. Lesinurad, which inhibits both URAT1 and OAT4, was administered at 200 milligrams daily in combination with a xanthine oxidase inhibitor, though it has been withdrawn from the market in some regions. Benzbromarone is a potent URAT1 inhibitor used in Europe and Asia but is unavailable in the United States due to concerns about hepatotoxicity.

#### Pegloticase (Recombinant Uricase)

Pegloticase is a PEGylated recombinant uricase that converts urate to allantoin, a highly water-soluble compound. It is administered as 8 milligrams intravenously every 2 weeks and is indicated for severe, refractory tophaceous gout in patients who have failed or are intolerant of xanthine oxidase inhibitors. Pegloticase achieves rapid and often dramatic urate reduction, frequently to undetectable serum levels. The principal limitation is the development of anti-drug antibodies in approximately 40 to 50 percent of patients, which cause loss of efficacy and infusion reactions. A pre-infusion serum urate level above 6 milligrams per deciliter signals anti-drug antibody formation and mandates immediate discontinuation of pegloticase. The MIRROR trial demonstrated that immunomodulation with methotrexate at 15 milligrams weekly as co-therapy significantly improved the sustained response rate from 39 percent to 71 percent, establishing methotrexate co-administration as standard practice for patients receiving pegloticase. Other immunomodulatory agents including mycophenolate mofetil, azathioprine, and leflunomide are under investigation as alternatives.

<image>A treat-to-target algorithm for gout urate-lowering therapy. Start with "Indications for ULT: ≥2 flares/year, tophi, or radiographic damage." First decision: Check HLA-B*5801 (mandatory in SE Asian, African American, Korean patients). If positive: AVOID allopurinol → use febuxostat or uricosuric. If negative: Start allopurinol 100 mg/day (50 mg if CKD stage ≥4). Titrate by 100 mg q2-4 weeks. Target: serum urate <6 mg/dL (<5 mg/dL for tophaceous gout). If target not met at max dose: Add uricosuric (probenecid) or switch to febuxostat. If refractory to oral ULT: Consider pegloticase 8 mg IV q2 weeks with methotrexate co-therapy. Include a parallel track showing anti-inflammatory prophylaxis (colchicine 0.6 mg daily or BID or low-dose NSAID) for 3-6 months when starting ULT, to prevent mobilization flares. Mark monitoring points: urate level q2-4 weeks during titration, then q6 months.</image>

| Agent | Class | Mechanism | Starting Dose | Target/Max Dose | Key Consideration | Contraindication/Caution |
|-------|-------|-----------|---------------|-----------------|-------------------|--------------------------|
| Allopurinol | XO inhibitor (purine analogue) | Inhibits xanthine oxidase | 100 mg/day (≤100 mg if CKD ≥3) | Titrate to SU <6; max 800 mg/day | **First-line** per ACR 2020; HLA-B*5801 testing mandatory in at-risk groups | HLA-B*5801 positive (DRESS/SJS-TEN risk) |
| Febuxostat | XO inhibitor (non-purine) | Selective XO inhibition | 40 mg/day | 80 mg/day | No renal dose adjustment; CARES CV warning vs FAST no difference | Second-line; FDA black box (CV risk debated) |
| Probenecid | Uricosuric | Blocks URAT1 reabsorption | 500 mg BID | Up to 2 g/day | Requires eGFR >50; ensure hydration and urine alkalinization | Uric acid nephrolithiasis; CKD |
| Pegloticase | Recombinant uricase | Converts urate → allantoin | 8 mg IV q2 weeks | 8 mg IV q2 weeks | **Refractory tophaceous gout** only; co-treat with MTX (MIRROR trial) | Pre-infusion SU >6 = anti-drug Ab → discontinue |

### Anti-inflammatory Prophylaxis During ULT Initiation

Flare prophylaxis is recommended for 3 to 6 months when initiating or adjusting urate-lowering therapy, as the mobilization of urate crystals during serum urate reduction can paradoxically trigger flares. Colchicine 0.6 milligrams daily or twice daily is the preferred prophylactic agent. A low-dose NSAID such as naproxen 250 milligrams twice daily is an alternative if colchicine is contraindicated, and low-dose prednisone at 10 milligrams daily or less represents a third-line option when both colchicine and NSAIDs are contraindicated. A critical principle is that flares occurring during ULT initiation should be treated with anti-inflammatory therapy while continuing the urate-lowering agent; ULT should never be stopped during an acute flare.

### Lifestyle and Dietary Modifications

Dietary modification plays a supportive role in gout management, though its impact on serum urate levels is modest compared to pharmacotherapy. Patients should limit purine-rich foods including organ meats, red meat, shellfish, and beverages containing high-fructose corn syrup. Alcohol intake should be limited, with beer having the highest purine content, followed by spirits, while moderate wine consumption may be acceptable. Low-fat dairy products are associated with lower urate levels through the uricosuric effects of casein and lactalbumin. Cherry consumption may reduce flare frequency based on observational data. Weight loss reduces serum urate and improves metabolic comorbidities. Adequate hydration helps prevent nephrolithiasis, and vitamin C at doses of 500 milligrams daily or more exerts a modest uricosuric effect.

### Medication Review

A careful review and modification of medications that promote hyperuricemia is an important component of gout management. Thiazide and loop diuretics should be substituted with alternative antihypertensives when clinically feasible. Low-dose aspirin should be continued for cardiovascular indications, as the gout risk it confers is modest and outweighed by its cardiovascular benefit. Cyclosporine should be replaced with tacrolimus when possible in transplant recipients. Conversely, certain medications possess inherent urate-lowering properties: losartan has mild uricosuric activity, fenofibrate similarly reduces serum urate, and SGLT2 inhibitors have emerging data supporting urate reduction, making them attractive choices for patients with coexistent diabetes, heart failure, or chronic kidney disease.

## Comorbidity Management

Gout functions as an independent cardiovascular risk factor, and comprehensive optimization of blood pressure, lipids, and glucose control is essential. The relationship between gout and chronic kidney disease is bidirectional: gout worsens CKD progression, while CKD promotes hyperuricemia. The FEATHER trial demonstrated that febuxostat slowed the rate of estimated glomerular filtration rate decline in patients with CKD and hyperuricemia. Uric acid stones account for approximately 10 percent of all kidney stones, and management includes urine alkalinization with potassium citrate and ULT to reduce stone formation. The metabolic syndrome should be addressed holistically, recognizing gout as one component of a broader cardiometabolic disease phenotype.

## Key Clinical Pearls

- Gout and septic arthritis can coexist; always send synovial fluid for crystal analysis AND Gram stain/culture
- HLA-B*5801 testing is mandatory before allopurinol in at-risk populations (SE Asian, African American, Korean)
- Start allopurinol low (100 mg) and titrate to target; there is no maximum dose ceiling in guidelines
- DO NOT stop ULT during an acute flare; add anti-inflammatory treatment and continue
- Pre-infusion urate >6 mg/dL on pegloticase indicates anti-drug antibody formation; discontinue immediately
- Febuxostat CV safety: CARES showed increased risk, but the larger FAST trial did not confirm this

<image>A polarized light microscopy illustration showing the synovial fluid appearance in gout. Show a high-power field with multiple needle-shaped monosodium urate crystals, some intracellular (phagocytosed by neutrophils) and some extracellular. Under compensated polarized light, show the crystals appearing bright yellow when parallel to the slow axis of the red compensator and bright blue when perpendicular (strong negative birefringence). Include a comparison inset showing CPPD crystals (rhomboid, weakly positive birefringent - blue when parallel, yellow when perpendicular) for contrast. Label the compensator axis orientation, crystal shapes, and birefringence patterns clearly.</image>

## References
1. FitzGerald JD, et al. 2020 American College of Rheumatology Guideline for Management of Gout. Arthritis Care Res. 2020;72(6):744-760.
2. Terkeltaub RA, et al. High versus low dosing of oral colchicine for early acute gout flare (AGREE trial). Arthritis Rheum. 2010;62(4):1060-1068.
3. White WB, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout (CARES). N Engl J Med. 2018;378(13):1200-1210.
4. Mackenzie IS, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol (FAST). Lancet. 2020;396(10264):1745-1757.
5. Botson JK, et al. Pegloticase in combination with methotrexate in patients with uncontrolled gout (MIRROR). JAMA. 2023;329(6):503-512.